NCT05402384View on ClinicalTrials.gov

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2027

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Interventions
DRUG

AVTX-801

"Medical grade D-galactose~dosage:2.0 g/kg/day"

DRUG

Placebo

Matching placebo

Trial Locations (1)

55905

Mayo Clinic Minnesota, Rochester

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Rare Diseases Clinical Research Network

NETWORK

collaborator

Children's Hospital of Philadelphia

OTHER

lead

Eva Morava-Kozicz

OTHER